← Back to Screener
Erasca, Inc. Common Stock (ERAS)
Price$11.97
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)269.68%
Price vs S&P 500 (4W)18.29%
VGM Score75.93
Market Capitalization$3.72B
All Metrics
Book Value / Share (Quarterly)$1.27
P/TBV (Annual)0.85x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.29
Price vs S&P 500 (YTD)213.62%
EPS (TTM)$-0.93
10-Day Avg Trading Volume5.89M
EPS Excl Extra (TTM)$-0.93
EPS (Annual)$-0.44
ROI (Annual)-38.30%
Cash / Share (Quarterly)$0.78
ROA (Last FY)-31.44%
EBITD / Share (TTM)$-1.00
ROE (5Y Avg)-40.36%
Cash Flow / Share (Annual)$-0.34
P/B Ratio9.46x
P/B Ratio (Quarterly)12.78x
Net Income / Employee (Annual)$-1,209,200
ROA (TTM)-64.30%
EPS Incl Extra (Annual)$-0.44
Current Ratio (Annual)10.04x
Quick Ratio (Quarterly)9.27x
3-Month Avg Trading Volume6.09M
52-Week Price Return662.42%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.25
52-Week High$24.28
EPS Excl Extra (Annual)$-0.44
CapEx CAGR (5Y)-33.03%
26-Week Price Return277.60%
Quick Ratio (Annual)9.77x
13-Week Price Return-22.97%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)9.52x
Enterprise Value$3.68B
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.97
3-Month Return Std Dev129.67%
Net Income / Employee (TTM)$-2,689,500
ROE (Last FY)-38.30%
EPS Basic Excl Extra (Annual)$-0.44
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.93
ROI (TTM)-77.01%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$2.76
Price vs S&P 500 (52W)638.05%
Year-to-Date Return221.77%
5-Day Price Return-13.39%
EPS Normalized (Annual)$-0.44
ROA (5Y Avg)-33.38%
Month-to-Date Return-6.78%
Cash Flow / Share (TTM)$-1.57
EBITD / Share (Annual)$-0.49
ROI (5Y Avg)-40.36%
EPS Basic Excl Extra (TTM)$-0.93
P/TBV (Quarterly)1.04x
P/B Ratio (Annual)3.25x
Book Value / Share (Annual)$1.14
Price vs S&P 500 (13W)-31.23%
Beta0.78x
Revenue / Share (TTM)$0.00
ROE (TTM)-77.01%
52-Week Low$1.21
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.60est. -0.21
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.06
4.06
4.06
4.06
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ERASErasca, Inc. Common Stock | — | — | B | $11.97 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Erasca is a clinical-stage oncology company developing targeted therapies for RAS/MAPK pathway-driven cancers. Its lead candidate, Naporafenib, is a pan-RAF inhibitor in development for NRAS-mutant melanoma and other RAS-driven solid tumors. The pipeline includes additional oral medications targeting downstream (ERK1/2 inhibitor) and upstream (SHP2 inhibitor) components of the RAS/MAPK pathway.